NAD(P)H:Quinone Oxidoreductase 1 Expression in Human Primary Melanotic Melanomas of the Skin

Francesco Zappa1*, Timothy Ward1, Ennio Pedrinis2, Alan Mc Gown1 and Nicholas Thatcher1

1CRC Department of Drug Development, Paterson Institute for Cancer Research and Christie Hospital NHS Trust, Manchester, UK
2Institute of Pathology of Southern Switzerland, Locarno, Switzerland

Abstract

NAD(P)H:quinone oxidoreductase 1 (NQ01; DT-diaphorase; DTD) is a two-electron reducing enzyme which is often over-expressed in cancers and can activate quinones to form cytotoxic species. This over-expression is used as target in the design of novel anti-cancer drugs. DTD is also expressed in normal tissues, but little is known about its “body mapping”. Because of the dearth of information on the cell-specific expression of DTD in pigment-producing cells of the skin, we analysed its expression in normal and tumoral samples. Twenty skin biopsies of primary malignant melanotic melanomas (ten with vertical invasion, ten with superficial spreading) were analysed by immunohistochemistry. In normal skin DTD expression was weak in all epidermal layers, including normal melanocytes. Malignant melanomas showed a very strong DTD expression in tumoral cells of all samples and in endothelial lining of peri-tumoral vessels.

These results suggest that DT-diaphorase may be a new marker that could be useful in determining the extent of a malignant melanocytic lesion, and also tend to support the potential of malignant melanomas as target for DTD-directed antitumour agents.

Keywords: DT-diaphorase; NQ01; Mitomycin toxicity; Quinones; Immunohistochemistry; Immunohistochemical marker; Malignant melanoma; Melanocytic lesion

Introduction

NAD(P)H:quinone oxidoreductase 1 (NQ01, DT-diaphorase; DTD) is a cytosolic enzyme that is known to catalyse a two-electron reduction of many xenobiotics, including some that are carcinogens [1-3] and some that are anti-neoplastic agents [4-6]. DT-diaphorase is able not only to reduce exogenous and endogenous quinones, and thereby to protect the cells against these reactive intermediates, but also to activate some quinones with cytostatic properties [7].

Compounds such as mitomycin C, streptonigrin, MeDZQ, E09, tirapazamine and RH1 are efficiently bioactivated by this enzyme [8-14].

RH1 is a compound selected for clinical development by the Cancer Research Campaign (CRC) and the NCI, and after its preclinical evaluation [15], it successfully underwent phase 1 evaluation [16].

Cells with elevated DT-diaphorase levels are generally more sensitive to bioreductive antitumour agents [10,17-19].

DT-diaphorase has been shown to be over-expressed in many cancerous tissues as opposed to normal tissues [20]. High levels of NQ01 gene expression are observed in liver, lung, colon and breast tumours in contrast to normal tissues of the same origin [21].

This enzyme is also ubiquitously expressed; a wide variation in NQ01 gene expression has been noted among various human tissues [22]; its overexpression has been described in isolated normal cells, i.e. podocytes [23] and cells of human reproductive system (Leydig’s cells) [24]; this observation may explain some quinones-related clinical toxicities, such as infertility and kidney failure.

Analyses of RNA indicate levels of NQ01 gene expression in tumours and in the tissue surrounding the tumours of patients with carcinoma that are 20- to 50-times higher than in normal individuals [25,26].

A dose correlation between DT-diaphorase expression explored by immunological methods and enzyme activity has been demonstrated [27,28]. Since DT-diaphorase plays a major role in activating quinone-containing anti-tumour agents in human carcinoma cell lines, the measurement of DT-diaphorase in clinical tumour samples is critical in designing adjuvant or palliative chemotherapy. Compounds that can be bioactivated by DT-diaphorase are becoming of increasing interest [12,13,29-32]. Because of the heterogeneous nature of DT-diaphorase expression, it is of primary interest to evaluate its expression and distribution in human normal and cancerous tissues. Surprisingly, DT-diaphorase has not been extensively investigated in human malignant melanomas or more generally in pigment-producing cells that are known to generate considerable amounts of ortho-quinones [33]. Very little has been previously reported on the level of expression of DT-diaphorase in human malignant melanomas of the skin. By a spectrophotometric method, a previous study detected high DT-diaphorase activity in melanoma cell cultures, in comparison to melanocytes isolated from normal skin or pigmented congenital naevus [33]. Another study analysed pathology specimens of conjunctival melanomas and primary acquired melanosis for DT-diaphorase expression by immunohistochemistry [34]. DT-diaphorase was detected in every examined section of primary acquired melanosis...
(cell-to-cell variability in the staining) and of melanoma of the conjunctiva (uniform staining). Interestingly, mitomycin C has been used in the treatment of both acquired melanosis and melanomas of the conjunctiva, suggesting that DT-diaphorase may play a role in the bioactivation of mitomycin C in these tumours. In our study, we performed an immunohistochemical analysis of DT-diaphorase expression in human primary malignant melanotic melanomas of the skin.

Materials and Methods

Human tissues

Archival samples of formalin-fixed paraffin-embedded tissues were supplied by the Institute of Pathology of Southern Switzerland, Locarno, Switzerland.

We analysed

- Ten bioptic samples of superficial spreading human malignant melanoma
- Ten bioptic samples of locally invasive human malignant melanomas

Methods

We performed an immunohistochemical analysis for the detection of DTD on tissue sections using anti-DTD antibodies.

Antibodies and Reagents

Anti-DTD monoclonal antibody (IgG1)-secreting hybridomas (clones A180 and B 771) were derived from a BALB-c mouse immunized with purified recombinant human DTD protein. All hybridoma cell lines were grown in spinner flasks in RPMI medium containing 50 units/ml penicillin, 50 µg/ml streptomycin, 1% L-glutamine and 10% fetal bovine serum in 5% CO₂ at 37°C to a concentration of 10⁶ cells/ml. Hybridoma tissue culture supernatants were prepared by centrifugation at 1800 rpm for 10 min and then stored at -80°C.

Prior to use supernatants were centrifuged at 14,000 rpm for 5 minutes. We demonstrated specificity of our proprietary antibody by pre-absorbing it with antigen (human recombinant DTD), and showing that immunohistochemical staining was completely blocked. We also performed a Western analysis on tissue extracts to confirm immunohistochemical staining specificity. Non-human reactive monoclonal mouse antibodies produced in tissue culture, subclass IgG1, were used as negative control reagent (Mouse IgG1 Negative Control Code No. X0931 DAKO A/S, Denmark).

Immunohistochemical method

Immunohistochemistry was performed on tissue sections (3 µm) cut from archival paraffin blocks. Sections were de-paraffinized in xylene and rehydrated through graded alcohol to running water, then placed in citrate buffer pH 6.0 and microwaved for two 3 min cycles. Endogenous peroxidase activity was blocked by adding Peroxidase Blocking Agent (DAKO En Vision Kit, Carpinteria, CA 93013 USA). Non-specific binding was blocked by adding 20% normal rabbit serum. Serial sections of each tissue sample were then incubated with either anti-DTD or control antibodies for 30 minutes at room temperature. The secondary antibody was added for 30 minutes (DAKOKIT, labelled Polymer HRP anti-mouse; peroxidase labelled polymer conjugated to goat anti-mouse immunoglobulins). Immunodetection was performed using a substrate-chromogen solution (DAKOKIT, hydrogen peroxide and 3,3’-diaminobenzidine chromogen). Slides were counterstained with haematoxylin, dehydrated through graded alcohols, mounted and photographed.

Figures 1A-1F: shows the immunohistochemical detection of DT-diaphorase in superficial spreading (epidermal invasion) malignant melanomas of the skin: Figure 1A: very strong expression of DT-diaphorase in malignant melanoma cells clusters in epidermis (E). Dermis (D) is not invaded (red line dividing epidermis from dermis). Figure 1B: negative control of Figure 1A (HE staining). Figures 1C-D: cancer cells clusters (arrows) in epidermis (E). Higher magnifications of Figure 1A. Figure 1E-F: another sample showing the very strong expression of DT-diaphorase in superficial spreading malignant melanoma cells invading the epidermis (E) but not the dermis (D). (Figure E, low magnification; figure F, high magnification).

Scoring of DTD immunostaining

The intensity of immunostaining of DTD (brown staining) was visually scored as 0 (negative), +1 (very weak), +2 (weak), +3 (strong), +4 (very intense) as previously reported for human lung cancers [35].

Results

All samples analysed were suitable for immunohistochemical analysis of DTD expression.

Superficial spreading malignant melanomas: in this histological variant cancer cells invade the epidermis but not the dermis. There was a very strong (score +4) DTD expression in tumoral cells of all
samples analysed (Figures 1A-1F). DTD expression in adjacent normal skin was very low to low (score +1/+2).

**Invasive malignant melanomas:** In this histological variant cancer cells infiltrate the dermis of the skin. There was a very strong (score +4) DTD expression in tumoral cells of all samples analysed (Figure 2A-2F). Endothelial lining of peri-tumoral vessels also showed strong to very strong (score +3/+4) staining for DTD (Figure 2F).

**Normal skin:** DTD expression was very weak to weak (score +1/+2) in all epidermal layers and in normal melanocytes, and absent in dermis and hypoderms (score 0) (Figure 3A). A strong to very strong (score +3/+4) staining for DTD was seen in sebaceous and sweat glands (Figure 3C-3D), and a strong to very strong staining (score +3/+4) was seen in endothelial lining of dermal vessels (score +3/+4) (Figure 3A). Interestingly, in one sample we did observe a well circumscribed epidermal area of strong DTD expression (Figure 3B). This could reflect a focal, protective response of the skin to external noxious agents.

There was no immunostaining in control sections when non-specific antibodies were used (Figures 1B, 2B, and 3D).

**Discussion**

Malignant melanoma is a tumor of melanocytes, cells derived embryologically from the neural crest. Most melanocytes are located in the basal layer of the epidermis, and produce melanin pigment, which is released into the epidermis and is responsible for skin colour. In fair-skinned individuals, melanocytes are subjected to considerable irradiation by visible and ultraviolet light. There is good epidemiological evidence from case-control studies to implicate sun exposure as a major causative factor for human melanoma [36]. The increasing incidence of malignant melanoma and the sparse availability of therapeutic resources implies the need to find new strategies to optimize its diagnosis and treatment. The prognosis of malignant melanoma is based on the stage of invasion at diagnosis, and is therefore strictly dependent on the ability of the pathologist to determine precisely the thickness of the melanoma (according to Breslow) and the level of invasion of the dermis. Other histological
and cytopathological factors with prognostic significance are the presence of ulceration and the number of mitosis, as well as the presence of satellite metastasis and in-transit metastasis around the tumor. The presence and the number of lymph nodes and of distant metastases are also of high prognostic relevance. Immunohistochemistry is the most valuable technique in diagnostic pathology. Many immunohistochemical markers of melanocytic lesions are available, some for diagnostic use, others with prognostic value. The most widely used melanocytic immunohistochemical markers in melanoma diagnosis on paraffin-embedded tissue blocks are the antigens SI00 (antibody S100) [37,38], gp 100 (antibodies HMB-45 and NKI-beteb), tyrosinase (antibody T311) and the melanoma antigen recognized by T cells, MART-1 (antibody A103) [39-47]. These antibodies are relevant not only for their histo-pathological diagnostic utility, but also with respect to the development of new anti-tumoral immunotherapeutical approaches and for screening potential candidates for these immunotherapies [48-50]. It is known that peptides derived from the antigens MART-1, tyrosinase and gp100 can generate immune responses because they are presented to T-lymphocytes (cytolytic T-cell-mediated immune response) [47,50,51]. In our study, a very strong expression of DT-diaphorase was found in malignant melanoma tumoral cells but not in normal skin. Interestingly, endothelial lining of vessels also expressed high levels of DT-diaphorase, revealing a potentially double cytotoxic action of DT-diaphorase, with both tumor cells and vessels. In fact, cells with elevated DT-diaphorase levels are intrinsically more sensitive to bioreductive antitumour agents such as Mitomicyn C, Streptonigrin or RH1, because of activation of these prodrugs upon reduction by DT-diaphorase. This reduction produces potent cytotoxic compounds that cross-link DNA and cause cell death. Indeed it is the increased expression of DT-diaphorase in tumor tissue that is used as a selective target for the design of new anti-cancer drugs. These results validate the interest in malignant melanomas as targets for DT-diaphorase-activated antitumour quinones and, in addition, propose that DT-diaphorase may be a novel immunohistochemical marker for use in determining the intra-epidermal and dermal extent of human malignant melanoma of the skin. The specificity of this new potential marker in distinguishing malignant melanocytic from benign melanocytic lesions and in evaluating malignant melanoma metastasis needs to be further evaluated.

Acknowledgments

Anti-DTD antibodies were a generous gift from Professor David Ross, Department of Pharmaceutical Sciences, School of Pharmacy and Cancer Center, University of Colorado Health Sciences Center, Denver, Colorado.

Francesco Zappa’s research is supported by an ESMO (European Society for Medical Oncology) grant.

References


